Clinical trials
Observational Melanoma trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 4 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 7 |
| Unknown status | 5 |
| Active, not recruiting | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AI Labs Group S.L | 4 |
| Bristol-Myers Squibb | 3 |
| Fundacion Clinic per a la Recerca Biomédica | 3 |
| Grupo Español Multidisciplinar de Melanoma | 3 |
| Fundación Academia Española de Dermatología | 2 |
| OncoHost Ltd. | 2 |
| Amgen | 1 |
| Azienda Ospedaliera di Perugia | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| German Cancer Research Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Melanoma | 29 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Neoplasms | 3 |
| Nevi and Melanomas | 3 |
| Skin Diseases | 3 |
| Skin Neoplasms | 3 |
| Basal Cell Carcinoma | 2 |
| Carcinoma, Renal Cell | 2 |
| Nevus | 2 |
| Nevus, Pigmented | 2 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.